Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-08-18

FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kesimpta (ofatumumab)

Snippet

SUPPL AP for KESIMPTA (OFATUMUMAB)